Research output per year
Research output per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
Dive into the research topics where Jeroen Hiltermann is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Research output
-
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC
Hiltermann, J., 2026, (Accepted/In press) In: ESMO Open.Research output: Contribution to journal › Article › Academic › peer-review
-
Cell-Free DNA Based Next-Generation Sequencing Does Not Differentiate Between Oligoprogression and Systemic Progression in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors-An Explorative Study
Rozendal, P., Kievit, H., van der Leest, P., Bahce, I., Pegtel, M., Groen, H. J. M., van Kempen, L. C., Hiltermann, T. J. N. & Schuuring, E., 21-Aug-2025, In: International Journal of Molecular Sciences. 26, 16, 15 p., 8087.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile20 Downloads (Pure) -
Changes in global quality of life after treatment with immune checkpoint inhibitors in patients receiving different treatment regimens for advanced stage lung cancer in the Netherlands: a 2015-2021 cohort study
Malhotra, A., Suazo-Zepeda, E., Vinke, P. C., de Bock, G. H., Maas, W. J., Hiltermann, J. T. J. N., Rachet, B., Leyrat, C. & Quaresma, M., 20-Feb-2025, In: BMJ Open. 15, 2, 12 p., e098062.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile41 Downloads (Pure) -
Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based model
Vaes, R. D. W., Cortiula, F., Lyu, S., Hiltermann, T. J. N., Houben, R., Degens, J., Hendriks, L. E. L. & Ruysscher, D. D., May-2025, In: Lung Cancer. 203, 9 p., 108541.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile35 Downloads (Pure) -
Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib
Zwierenga, F., Muntinghe-Wagenaar, M. B., Rozendal, P., de Langen, A. J., Hendriks, L. E. L., van den Heuvel, M., van der Leest, C., Hashemi, S. M. S., van der Leest, P., Hiltermann, T. J. N., Schuuring, E. & van der Wekken, A. J., Jul-2025, In: Targeted oncology. 20, 4, p. 663-677 15 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile10 Downloads (Pure)
Activities
-
Efficacy and Safety of Rilvegostomig (Anti-PD-1/TIGIT) in Checkpoint Inhibitor-Naïve Metastatic NSCLC: ARTEMIDE-01
Yoshida, T. (Speaker) & Hiltermann, J. (Contributor)
28-Mar-2026Activity: Talk and presentation › Academic presentation › Academic
-
Interim analysis of a randomized study of 1L BMS-986012 (anti-fucosyl-GM-1) with Chemotherapy and nivolumab in ES-SCLC
Sugawara, S. (Speaker) & Hiltermann, J. (Contributor)
6-Mar-2025Activity: Talk and presentation › Academic presentation › Academic
-
Efficacy and safety of rilvegostomig, an anti-PD-1/TIGIT bispecific antibody, for checkpoint inhibitor (CPI)-naïve metastatic non-small-cell lung cancer (mNSCLC): ARTEMIDE-01
Cho, B. C. (Speaker) & Hiltermann, J. (Contributor)
20-Oct-2025Activity: Talk and presentation › Academic presentation › Academic
-
Molecular Tumor Board: the role in the journey towards treatment decision-making of complex or rare variants
Hiltermann, J. (Speaker), Schuuring, E. (Speaker), Timens, W. (Speaker) & de Jager, V. (Speaker)
12-Feb-2025Activity: Talk and presentation › Professional or public presentation › Professional
File -
Longkanker screening redt levens, maar is niet genoeg
Hiltermann, J. (Speaker)
31-Jan-2025Activity: Talk and presentation › Professional or public presentation › Professional
File
Press/Media
-
Neo- en perioperatieve chemo-immunotherapie bij NSCLC
04/04/2025
1 Media contribution
Press/Media: Expert Comment › Professional
-
TLCR Outstanding Author interview
24/02/2025
1 Media contribution
Press/Media: Expert Comment › Professional
-
Rilvegostomig Elicits Responses in CPI-Naive NSCLC, Irrespective of PD-L1 TPS Status
10/09/2024
1 Media contribution
Press/Media: Expert Comment › Popular
-
Terminaal zieke John Franke strijdt met podcast voor bevolkingsonderzoek naar longkanker
01/08/2022
1 Media contribution
Press/Media: Expert Comment › Popular
-